Want to see JP:4889 full AI Analyst Report?

Renascience Inc. (4889) Price & Analysis

0 Followers

4889 Stock Chart & Stats

¥1436.00

-¥9.00(-2.89%)

At close: Jan 08 4:00 PM EST

¥1436.00

-¥9.00(-2.89%)

Day’s Range― - ―

52-Week Range¥1,101.00 - ¥2,342.00

Previous CloseN/A

Volume77.30K

Average Volume (3M)441.11K

Market Cap

¥16.70B

Enterprise Value¥18.26K

Total Cash (Recent Filing)¥3.40B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.74

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-23.39

Shares Outstanding13,776,900

10 Day Avg. Volume357,940

30 Day Avg. Volume441,113

Financial Highlights & Ratios

PEG Ratio0.20

Price to Book (P/B)6.50

Price to Sales (P/S)315.22

P/FCF Ratio-74.18

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage (zero Debt)Reducing debt to zero materially lowers fixed financial obligations and interest risk, giving management durable optionality to fund R&D or licensing from equity or cash. Low leverage improves solvency and strategic flexibility over the next several quarters to years.

Consistently High Gross MarginsSustained high gross margins indicate the core product economics or technology have strong per-unit profitability potential. If operating leverage is achieved or SG&A is managed, margins could support durable profitability as revenues scale or stabilize.

Equity Growth Supporting Asset ExpansionGrowing equity provides a firmer capital base for investments in pipelines, capacity, or partnerships without increasing leverage. A stronger equity position supports long-term program funding and reduces reliance on short-term debt markets.

Bears Say

Persistent Negative Operating And Free Cash FlowChronic cash burn erodes runway and creates a structural need for external financing or dilutive capital raises, constraining strategic choices. Negative OCF/FCF undermines ability to scale operations or invest sustainably without repeated funding.

Volatile, Declining Revenue TrendSharp, persistent revenue declines and volatility signal weak commercial traction or dependency on lumpy contracts. This impairs the firm’s ability to leverage fixed costs, hinders predictable margin improvement, and raises execution risk for long-term plans.

Structural Unprofitability And Earnings Quality ConcernsIrregular profitability and a profit not backed by operating cash flow indicate earnings volatility and low quality. Inconsistent returns on equity and episodic profits make it difficult to rely on internal cash generation for sustaining R&D or commercialization.

4889 FAQ

What was Renascience Inc.’s price range in the past 12 months?

Renascience Inc. lowest stock price was ¥1101.00 and its highest was ¥2342.00 in the past 12 months.

What is Renascience Inc.’s market cap?

Renascience Inc.’s market cap is ¥16.70B.

When is Renascience Inc.’s upcoming earnings report date?

Renascience Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 55 days.

How were Renascience Inc.’s earnings last quarter?

Renascience Inc. released its earnings results on Aug 14, 2026. The company reported -¥5.95 earnings per share for the quarter.

Is Renascience Inc. overvalued?

According to Wall Street analysts Renascience Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Renascience Inc. pay dividends?

Renascience Inc. does not currently pay dividends.

What is Renascience Inc.’s EPS estimate?

Renascience Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Renascience Inc. have?

Renascience Inc. has 13,776,900 shares outstanding.

What happened to Renascience Inc.’s price movement after its last earnings report?

Renascience Inc. reported an EPS of -¥5.95 in its last earnings report. Following the earnings report the stock price went up 3.09%.

Which hedge fund is a major shareholder of Renascience Inc.?

Currently, no hedge funds are holding shares in JP:4889

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Renascience Inc.

Renascience Inc., established in 2000 and based in Tokyo, Japan, is actively engaged in pioneering and bringing to market pharmaceuticals and medical devices throughout Japan. The company's pipeline includes RS5614, a PAI-1 inhibitor that has reached Phase 3 clinical trials for a wide range of indications such as chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets. Another PAI-1 inhibitor, RS5441, is currently in Phase 1 trials for various dermatological conditions. Additionally, RS8001, a water-soluble vitamin, is undergoing Phase 2 clinical development for the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder. Beyond its pharmaceutical ventures, Renascience is also advancing the RS9001 disposable ultrafine endoscope, alongside developing artificial intelligence-driven medical solutions and comprehensive diagnostic tools.